Skip Navigation


NDT Advance Access originally published online on November 29, 2007
Nephrology Dialysis Transplantation 2008 23(4):1330-1335; doi:10.1093/ndt/gfm793
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
23/4/1330    most recent
gfm793v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Taes, Y. E. C.
Right arrow Articles by Delanghe, J. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taes, Y. E. C.
Right arrow Articles by Delanghe, J. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Guanidino compounds after creatine supplementation in renal failure patients and their relation to inflammatory status

Youri E. C. Taes1, Bart Marescau2, An De Vriese3, Peter P. De Deyn2, Eva Schepers4, Raymond Vanholder4 and Joris R. Delanghe1

1 Laboratory Clinical Chemistry, University Hospital Ghent 2 Laboratory of Neurochemistry and Behavior, University of Antwerp, Institute Born-Bunge, Antwerp 3 Renal Unit, Department of Internal Medicine, Algemeen Ziekenhuis St Jan, Brugge 4 Renal Unit, Department of Internal Medicine, University Hospital Ghent, Belgium

J. Delanghe, Laboratory Clinical Chemistry 2P8, University Hospital Ghent, De Pintelaan 185, 9000 Ghent, Belgium. Tel: +32-9-240-29-56; Fax: +32-9-240-49-85; E-mail: Joris.Delanghe{at}UGent.be



  Abstract

Background. Specific guanidino compounds have been described as uraemic toxins and their concentrations are increased in renal failure due to dimished glomerular filtration, whereas the guanidino compound creatine is used as a performance-enhancing substance in athletes. The present study investigates the effects of creatine supplementation on plasma guanidino compounds in a chronic haemodialysis population.

Methods. Twenty male haemodialysis patients were included in a placebo-controlled cross-over trial. Patients were treated with creatine (2 g/day) or placebo during two treatment periods of 4 weeks, separated by a washout of 4 weeks. Plasma guanidino compounds and routine biochemical parameters were determined, as well as the prognostic inflammatory and nutritional index (PINI).

Results. Upon creatine supplementation, guanidinoacetate concentrations decreased by 15%, due to inhibition of creatine synthesis. Concentrations of {alpha}-keto-{delta}-guanidinovaleric acid increased three-fold and argininic acid concentrations doubled. Guanidinosuccinate concentrations did not change, but correlated inversely with CRP (r = –0.736; P = 0.001), PINI-score (r = –0.716; P = 0.002) and correlated positively with plasma urea concentration (r = 0.54; P = 0.02).

Conclusions. Creatine supplementation in haemodialysis patients significantly altered the concentration of specific guanidino compounds. Guanidinosuccinate correlated positively with plasma urea and negatively with inflammation markers.

Keywords: creatine; guanidino compounds; neurotoxins; urea cycle

Received for publication: 16. 8.07
Accepted in revised form: 11.10.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.